Literature DB >> 18325186

Are patients with familial hypercholesterolaemia well managed in lipid clinics? An audit of eleven clinics from the Department of Health Familial Hypercholesterolaemia Cascade Testing project.

S G Hadfield1, S Horara, B J Starr, S Yazdgerdi, D Bhatnagar, R Cramb, S Egan, R Everdell, G Ferns, A Jones, C B Marenah, J Marples, P Prinsloo, A Sneyd, M F Stewart, L Sandle, T Wang, M S Watson, S E Humphries.   

Abstract

BACKGROUND: Familial hypercholesterolaemia (FH) is an autosomal co-dominant disorder which is relatively common, leads to high levels of LDL-cholesterol and if untreated to early coronary heart disease. An audit of current practice at National Health Service Trusts in England was undertaken to determine whether FH patients meet the diagnostic criteria for FH; are being offered appropriate advice and treatment; and to what extent their families are contacted and offered testing for the disorder.
METHODS: Medical records of known FH patients (over 18 years of age and diagnosed before 31 December 2003) were accessed to obtain information on diagnosis, treatment and family tracing.
RESULTS: The records of 733 FH patients were examined, 79% met the UK 'Simon Broome' register criteria for the diagnosis of definite or possible FH. Analyses showed that patients were usually offered appropriate advice and treatment, with 89% being on a statin. However, the audit indicated a high variability in family tracing between the sites, with significant differences in the frequency of inclusion of a family pedigree in the notes (range 1-71%, mean 35%); the general practitioner (GP) being advised that first-degree relatives should be tested (range 4-52%, mean 27%); and the proportion of relatives contacted and tested (range 6-50%, mean 32%).
CONCLUSION: FH patients are well cared for in lipid clinics in England, are being given appropriate lifestyle advice and medication, but an increase in recording of LDL-cholesterol levels may lead to improvements in their management. Practice in family tracing appears to vary widely between clinics.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18325186     DOI: 10.1258/acb.2007.007078

Source DB:  PubMed          Journal:  Ann Clin Biochem        ISSN: 0004-5632            Impact factor:   2.057


  7 in total

1.  Treatment Gaps in Adults With Heterozygous Familial Hypercholesterolemia in the United States: Data From the CASCADE-FH Registry.

Authors:  Emil M deGoma; Zahid S Ahmad; Emily C O'Brien; Iris Kindt; Peter Shrader; Connie B Newman; Yashashwi Pokharel; Seth J Baum; Linda C Hemphill; Lisa C Hudgins; Catherine D Ahmed; Samuel S Gidding; Danielle Duffy; William Neal; Katherine Wilemon; Matthew T Roe; Daniel J Rader; Christie M Ballantyne; MacRae F Linton; P Barton Duell; Michael D Shapiro; Patrick M Moriarty; Joshua W Knowles
Journal:  Circ Cardiovasc Genet       Date:  2016-03-24

2.  Two years after molecular diagnosis of familial hypercholesterolemia: majority on cholesterol-lowering treatment but a minority reaches treatment goal.

Authors:  Roeland Huijgen; Iris Kindt; Sjoerd B J Verhoeven; Eric J G Sijbrands; Maud N Vissers; John J P Kastelein; Barbara A Hutten
Journal:  PLoS One       Date:  2010-02-15       Impact factor: 3.240

Review 3.  My Approach to the Patient With Familial Hypercholesterolemia.

Authors:  Maya S Safarova; Iftikhar J Kullo
Journal:  Mayo Clin Proc       Date:  2016-06       Impact factor: 7.616

4.  Long-Term Cardiovascular Risk in Heterozygous Familial Hypercholesterolemia Relatives Identified by Cascade Screening.

Authors:  Kasper Aalbæk Kjærgaard; Morten Krogh Christiansen; Morten Schmidt; Morten Smærup Olsen; Henrik Kjærulf Jensen
Journal:  J Am Heart Assoc       Date:  2017-06-26       Impact factor: 5.501

5.  How do the experiences and beliefs of adults and children with heterozygous familial hypercholesterolaemia influence their adherence to treatment? A systematic review of qualitative evidence protocol.

Authors:  Fiona J Kinnear; Rachel Perry; Aidan Searle; Julian P Hamilton-Shield; Fiona E Lithander
Journal:  Syst Rev       Date:  2018-08-16

6.  Prevalence and Treatment of Familial Hypercholesterolemia and Severe Hypercholesterolemia in Older Adults in Ontario, Canada.

Authors:  Leo E Akioyamen; Anna Chu; Jacques Genest; Douglas S Lee; Husam Abdel-Qadir; Cynthia A Jackevicius; Patrick R Lawler; Maneesh Sud; Jacob A Udell; Harindra C Wijeysundera; Dennis T Ko
Journal:  CJC Open       Date:  2022-05-20

7.  Design of a Controlled Trial of Cascade Screening for Hypercholesterolemia: The (CASH) Study.

Authors:  Iftikhar J Kullo; Kent R Bailey
Journal:  J Pers Med       Date:  2018-08-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.